Stocks of Glaukos Corporation (NYSE:GKOS) traded higher last session on Wall Street, down -0.24% to $45.25.
GKOS stock price is now -5.97% away from the 50-day moving average and -7.84% away from the 200-day moving average. The market capitalization of the company currently stands at $2.22B.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
With the price target of $48, Mizuho recently initiated with Neutral rating for Glaukos Corporation (NYSE: GKOS). On December 19, 2022, JP Morgan Upgraded its previous ‘Underweight’ rating to ‘Neutral’ on the stock reducing its target price from $48 to quote $42, while ‘Citigroup’ rates the stock as ‘Buy’.
In other news, Kliman Gilbert H, Director sold 3,362 shares of the company’s stock on Aug 05. The stock was sold for $178,229 at an average price of $53.01. Upon completion of the transaction, the Director now directly owns 0 shares in the company, valued at $0.0. Insiders disposed of 454,346 shares of company stock worth roughly $20.56 million over the past 1 year. A total of 1.80% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in GKOS stock. A new stake in Glaukos Corporation shares was purchased by BRAIDWELL LP during the first quarter worth $75,199,000. PEREGRINE CAPITAL MANAGEMENT LLC invested $5,224,000 in shares of GKOS during the first quarter. In the first quarter, GILDER GAGNON HOWE & CO LLC acquired a new stake in Glaukos Corporation valued at approximately $2,910,000. EXODUSPOINT CAPITAL MANAGEMENT, LP acquired a new stake in GKOS for approximately $1,386,000. AMALGAMATED FINANCIAL CORP. purchased a new stake in GKOS valued at around $1,036,000 in the second quarter. In total, there are 309 active investors with 95.70% ownership of the company’s stock.
Monday’s opening bell rang with an opening price of $44.86 for Glaukos Corporation (NYSE: GKOS). During the past 12 months, Glaukos Corporation has had a low of $33.33 and a high of $64.49. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 6.10, and a quick ratio of 5.60. The fifty day moving average price for GKOS is $48.12 and a two-hundred day moving average price translates $49.10 for the stock.
The latest earnings results from Glaukos Corporation (NYSE: GKOS) was released for Sep, 2022. According to the Medical Devices Company, earnings per share came in at -$0.45, beating analysts’ expectations of -$0.52 by 0.07. This compares to -$0.46 EPS in the same period last year. The net profit margin was -35.10% and return on equity was -17.70% for GKOS. The company reported revenue of $71.23 million for the quarter, compared to $73.24 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -2.75 percent. For the current quarter, analysts expect GKOS to generate $68.02M in revenue.
Glaukos Corporation(GKOS) Company Profile
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company’s product pipeline includes iStent Infinite, a three stents product that is designed for use as a standalone procedure in patients with refractory glaucoma; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.
